Tracking MAPK-Dependent CD38 Upregulation by All-Trans Retinoic Acid in Human Leukemia Using 89 Zr Immuno-PET
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Mina Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea. Hauptthemen laut MEDLINE: ADP-ribosyl Cyclase 1, Zirconium, Tretinoin, Positron-Emission Tomography. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Anti-CD38 antibodies (Abs) are promising immunotherapeutics for hematologic malignancies, but their efficacy in leukemias often requires pharmacologic upregulation of CD38. Immuno-PET provides a noninvasive strategy to evaluate such target modulation in vivo. Cysteine site-specific 89Zr labeling of anti-CD38 Abs was performed using deferoxamine-maleimide. CD38-specific target binding was confirmed in three human myeloma and two leukemia cell lines. Total and surface expressed CD38 levels were assessed by Western blotting and flow cytometry. Immuno-PET imaging and biodistribution studies were conducted in murine leukemia models. All-trans retinoic acid (ATRA) was used to stimulate CD38 expression. Myeloma and MOLT4 leukemia cells showed variable baseline CD38, while HL60 cells exhibited negligible levels. All tumor cells demonstrated 89Zr-OKT10 IgG and 89Zr-daratumumab (Fc-silenced) binding that paralleled surface CD38 expression. ATRA upregulated CD38 in all tested cells, including a marked induction in HL60 cells, all accompanied by corresponding elevations in 89Zr-CD38 Ab binding. On 89Zr-OKT10 IgG PET, MOLT4 tumors showed high uptake that was reduced by 67.9% with unlabeled Ab, but HL60 tumors showed low uptake and high liver accumulation, limiting ATRA assessment. 89Zr-daratumumab produced lower liver uptake and improved MOLT4 and HL60 tumor visualization; ATRA modestly increased MOLT4 tumor uptake and substantially enhanced HL60 tumor uptake from 8.0 ± 1.7 %ID/g to 14.7 ± 3.1 %ID/g (83.8% increase; P < 0.005). Mechanistic studies demonstrated ATRA-induced ERK1/2 activation in HL60 cells that was abolished by the MAPK inhibitor U0126; U0126 also suppressed CD38 induction and 89Zr-CD38 Ab uptakes in all tested tumor cells. Furthermore, U0126 blocked ATRA-induced HL60 tumor 89Zr-daratumumab uptake in vivo. Western blots and immunohistochemistry confirmed ATRA-induced HL60 tumor CD38 elevation, which was partly reversed by U0126. Thus, 89Zr immuno-PET enables noninvasive monitoring of ATRA-driven CD38 upregulation via MAPK signaling and supports its potential utility for optimizing combination strategies in leukemias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
- Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06355, Korea.
ORCID-Profile: Kyung-Han Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, M., Koo, H. J., Jung, K. H., Kim, J. L., Kim, G., Lee, H., & Lee, K. H. (2026). Tracking MAPK-Dependent CD38 Upregulation by All-Trans Retinoic Acid in Human Leukemia Using 89 Zr Immuno-PET. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01474
Vancouver
Kim M, Koo HJ, Jung KH, Kim JL, Kim G, Lee H, et al. Tracking MAPK-Dependent CD38 Upregulation by All-Trans Retinoic Acid in Human Leukemia Using 89 Zr Immuno-PET. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01474
BibTeX
@article{Kim2026,
author = {Kim, Mina and Koo, Hyun-Jung and Jung, Kyung-Ho and Kim, Jung Lim and Kim, Giro and Lee, Hyunjong and Lee, Kyung-Han},
title = {Tracking MAPK-Dependent CD38 Upregulation by All-Trans Retinoic Acid in Human Leukemia Using 89 Zr Immuno-PET},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01474}
}
EUVIMED